Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + ...( IRVINE Calif. June 12 /- Cardioge...),Health

IRVINE, Calif., June 12 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products for cardiac revascularization, today announced a scientific presentation that describes the use of the PHOENIX delivery system combining transmyocardial revascularization (TMR) with autologous bone marrow derived stem cells.

The presentation titled "Transmyocardial Revascularization Combined with Concentrated Autologous Stem Cells," is to be presented by Guillermo Reyes, M.D. of La Princesa Hospital (Madrid, Spain) at the 10th annual meeting of the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) on June 12, 2008 in Boston. The abstract of the presentation is available at http://www.ismics.org/abstracts/2008/MP5.html.

Dr. Reyes reports on the use of the PHOENIX system, a Holmium YAG Laser TMR and biologic combination delivery system manufactured by Cardiogenesis. Dr. Reyes is presenting on a series of 9 patients with diffuse coronary artery disease and medically refractory class III/IV angina that were treated by the application of TMR in combination with bone marrow derived stem cells in targeted ischemic heart muscle. At an average follow up of 6 months:
-- All patients experienced at least a two class reduction in angina;

-- 7 patients were angina free;

-- Sublingual nitrate use pre procedure was 37 per patient per month

compared to 4 per month at follow up (p=0.03);

-- and there were no perioperative adverse events including no

arrhythmias.

The hypothesis for the study is an enhanced cell uptake and angiogenic effect when delivering concentrated bone marrow derived stem cells to the stimulated tissue border zone surrounding the TMR channels at the time of surgery.

"These initial clinical results utilizing the PHOENIX delivery system are very prom
'/>"/>